AI drug discovery is finding cures faster — but labs can't keep up with the data
ai tools are accelerating drug target identification, but physical lab validation and low-fidelity historical data are creating bottlenecks that delay clinical trials.
ai is transforming drug discovery from empirical screening to predictive design, allowing researchers to identify viable compounds without physical testing. however, this creates a new bottleneck where labs must validate a higher volume of complex, ai-generated candidates using traditional low-throughput methods. furthermore, reliance on public datasets has caused a 'data wall', forcing models to hit diminishing returns as they lack the high-fidelity data needed to predict kinetics reliably. these issues require investment in information-rich lab technologies and better data pipelines to integrate ai effectively.